3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Phase 2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Pancreatic Neoplasms
1
Neuroectodermal Tumors
1
Nervous System Diseases
1
Neoplasms, Neuroepithelial
1
Neoplasms, Nerve Tissue
1
Neoplasms
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Disease
1
CRC
1
Brain Neoplasms
1
Interventions
Temozolomide
73
Bevacizumab
58
Radiotherapy
40
Radiosurgery
28
Carboplatin
23
Nivolumab
17
Etoposide
17
Cisplatin
17
pembrolizumab
16
Irinotecan
16
Ipilimumab
15
Magnetic Resonance Spectroscopy
14
Erlotinib Hydrochloride
14
Cyclophosphamide
14
Carmustine
14
Pemetrexed
13
Topotecan
10
Surgical Procedures, Operative
10
Capecitabine
10
Lapatinib
9
Filgrastim
9
Trastuzumab
8
Thalidomide
8
Sunitinib
8
Paclitaxel
8
Lomustine
8
Aminolevulinic Acid
8
encorafenib
7
binimetinib
7
Vincristine
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Brain Neoplasms
×
Oncolytic Virotherapy
×
Clear all
NCT02798406
2021-07-15
CAPTIVE
DNAtrix, Inc.
Phase 2
Completed
49 enrolled